Compare BILL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | IMNM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2019 | 2020 |
| Metric | BILL | IMNM |
|---|---|---|
| Price | $45.09 | $22.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $57.90 | $32.80 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.07 | 51.40 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $1,462,570,000.00 | $6,941,000.00 |
| Revenue This Year | $14.18 | N/A |
| Revenue Next Year | $13.83 | $1,127.34 |
| P/E Ratio | $640.29 | ★ N/A |
| Revenue Growth | ★ 13.36 | N/A |
| 52 Week Low | $31.41 | $8.67 |
| 52 Week High | $57.21 | $27.65 |
| Indicator | BILL | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 72.04 | 53.56 |
| Support Level | $42.06 | $19.28 |
| Resistance Level | $46.70 | $23.25 |
| Average True Range (ATR) | 1.76 | 1.31 |
| MACD | 0.73 | -0.07 |
| Stochastic Oscillator | 91.00 | 36.55 |
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.